MedPath

Alfuzosin

Generic Name
Alfuzosin
Brand Names
Uroxatral, Xatral
Drug Type
Small Molecule
Chemical Formula
C19H27N5O4
CAS Number
81403-80-7
Unique Ingredient Identifier
90347YTW5F

Overview

Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.

Background

Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.

Indication

Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).

Associated Conditions

  • Benign Prostatic Hyperplasia (BPH)

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Physicians Total Care, Inc.
54868-6329
ORAL
10 mg in 1 1
3/27/2012
DirectRX
61919-349
ORAL
10 mg in 1 1
1/17/2020
Aurobindo Pharma Limited
65862-249
ORAL
10 mg in 1 1
1/6/2024
Physicians Total Care, Inc.
54868-5046
ORAL
10 mg in 1 1
8/30/2012
Golden State Medical Supply, Inc.
51407-829
ORAL
10 mg in 1 1
10/9/2023
Northwind Pharmaceuticals, LLC
51655-087
ORAL
10 mg in 1 1
1/19/2023
Denton Pharma, Inc. DBA Northwind Pharmaceuticals
70934-306
ORAL
10 mg in 1 1
11/23/2021
Cipla USA Inc.
69097-844
ORAL
10 mg in 1 1
5/28/2020
Exelan Pharmaceuticals Inc.
76282-302
ORAL
10 mg in 1 1
12/1/2022
Wockhardt USA LLC.
64679-738
ORAL
10 mg in 1 1
11/26/2019

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath